DST regulates cisplatin resistance in colorectal cancer via PI3K/Akt pathway
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgae104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Jianwei Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan 364000, Fujian Province, China. Hauptthemen laut MEDLINE: Cisplatin, Colorectal Neoplasms, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Startup Fund for Scientific Research, Fujian Medical University, Longyan City Science and Technology Plan.
Abstract (Originalsprache)
Objectives
Dystonin (DST), a potential tumor suppressor gene, plays a crucial role in regulating cancer cell proliferation and resistance to chemotherapy. However, DST’s specific role in colorectal cancer (CRC) has not been thoroughly investigated, and this study aims to elucidate its molecular role in modulating cisplatin (DDP) resistance in CRC.
Methods
DST expression was analyzed in CRC tumors, DDP-resistant CRC tissues, paracancer tissues, and normal tissues. Lentiviral overexpression and shRNA knockdown were conducted in advanced CRC and DDP-resistant cell lines to assess cell viability, apoptosis, invasion, migration, proliferation, and angiogenesis. Xenograft mouse models studied DST’s impact on CRC tumor growth and DDP resistance in vivo.
Results
DST expression was significantly reduced in CRC tumor and DDP-resistant CRC tissues compared to paracancer and normal tissues (P < .001). Upregulating DST inhibited CRC and DDP-resistant cell viability, proliferation, invasion, and migration while promoting apoptosis. DST overexpression also reduced angiogenesis and attenuated DDP-induced cytotoxicity in CRC cells. Mechanistically, DST upregulation suppressed DDP resistance in CRC cells via the PI3K/Akt signaling pathway. DST upregulation reduced CRC tumor growth and mitigated DDP resistance, in vivo.
Conclusion
DST plays a crucial role in limiting CRC progression and overcoming DDP resistance, suggesting potential for targeted CRC therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan 364000, Fujian Province, China.
ORCID-Profile: Dong Lin
Förderung
- Startup Fund for Scientific Research
- Fujian Medical University
- Longyan City Science and Technology Plan
Zitieren
APA
Yu, J., Deng, X., Lin, X., Xie, L., Guo, S., Lin, X., & Lin, D. (2025). DST regulates cisplatin resistance in colorectal cancer via PI3K/Akt pathway. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae104
Vancouver
Yu J, Deng X, Lin X, Xie L, Guo S, Lin X, et al. DST regulates cisplatin resistance in colorectal cancer via PI3K/Akt pathway. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgae104
BibTeX
@article{Yu2025,
author = {Yu, Jianwei and Deng, Xueqiong and Lin, Xueqin and Xie, Li and Guo, Sisi and Lin, Xiaoliang and Lin, Dong},
title = {DST regulates cisplatin resistance in colorectal cancer via PI3K/Akt pathway},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgae104}
}
EUVIMED